Paolo Bonfanti

List of Publications by Year
in descending order

169 papers	10,932 citations	94433 37 h-index	37204 96 g-index
171 all docs	171 docs citations	171 times ranked	18794 citing authors

#	Article	IF	Citations
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,983
2	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,749
3	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	27.0	1,548
4	Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 765-774.	10.7	386
5	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	11.9	357
6	High rates of 30-day mortality in patients with cirrhosis and COVID-19. Journal of Hepatology, 2020, 73, 1063-1071.	3.7	279
7	An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight, 2021, 6, .	5.0	269
8	X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Science Immunology, 2021, 6, .	11.9	267
9	Hospital-Acquired Infections in Critically Ill Patients With COVID-19. Chest, 2021, 160, 454-465.	0.8	225
10	Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program. Clinical Infectious Diseases, 2013, 56, 1004-1017.	5.8	178
11	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1899-1913.	2.6	137
12	Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemaseâ€“Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clinical Infectious Diseases, 2021, 73, 1664-1676.	5.8	130
13	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	7.1	110
14	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. Journal of Hepatology, 2019, 70, 379-387.	3.7	109
15	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of Translational Medicine, 2020, 18, 405.	4.4	98
16	Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 236-245.	2.1	97
17	HIV and Metabolic Syndrome. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 426-431.	2.1	97
18	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. European Journal of Internal Medicine, 2020, 82, 38-47.	2.2	88

#	Article	IF	Citations
19	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thrombosis and Haemostasis, 2021, 121, 1054-1065.	3.4	87
20	Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 236-245.	2.1	79
21	Frailty index predicts poor outcome in COVID-19 patients. Intensive Care Medicine, 2020, 46, 1634-1636.	8.2	78
22	Risk Factors for Hepatotoxicity in Patients Treated With Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 316-318.	2.1	73
23	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. Journal of Hepatology, 2019, 71, 1106-1115.	3.7	69
24	Neutralizing typeâ€I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVIDâ€19. Immunology and Cell Biology, 2021, 99, 917-921.	2.3	69
25	Weight Gain: A Possible Side Effect of All Antiretrovirals. Open Forum Infectious Diseases, 2017, 4, ofx239.	0.9	68
26	Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project. Biomedicine and Pharmacotherapy, 2008, 62, 6-11.	5.6	59
27	The Burden of Metabolic Diseases Amongst HIV Positive Patients on HAART Attending the Johannesburg Hospital. Current HIV Research, 2011, 9, 247-252.	0.5	57
28	Delirium in Patients with <scp>SARSâ€CoV</scp>â€2 Infection: A Multicenter Study. Journal of the American Geriatrics Society, 2021, 69, 293-299.	2.6	50
29	Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia. JAMA Network Open, 2021, 4, e2136246.	5.9	50
30	Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study. Journal of Infection, 2008, 57, 33-40.	3.3	49
31	Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. Aids, 2017, 31, 455-457.	2.2	47
32	Factors Associated With Weight Gain in People Treated With Dolutegravir. Open Forum Infectious Diseases, 2020, 7, ofaa195.	0.9	47
33	The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. Biomedicine and Pharmacotherapy, 2000, 54, 45-49.	5.6	46
34	An Italian Approach to Postmarketing Monitoring: Preliminary Results From the SCOLTA (Surveillance) Tj ETQq0 0 0 rgBT /Overlock 10 T Acquired Immune Deficiency Syndromes (1999), 2005, 39, 317-320.	2.1	46
35	Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. Aids, 2013, 27, 381-389.	2.2	46
36	Effectiveness of dolutegravirâ€based regimens as either firstâ€line or switch antiretroviral therapy: data from the Icona cohort. Journal of the International AIDS Society, 2019, 22, e25227.	3.0	46

#	Article	IF	Citations
37	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
38	Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infectious Diseases, 2018, 18, 357.	2.9	42
39	The Pattern of Non-AIDS-defining Cancers in the HIV Population: Epidemiology, Risk Factors and Prognosis. A Review. Current HIV Research, 2019, 17, 1-12.	0.5	40
40	Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study. Infection, 2016, 44, 589-597.	4.7	39
41	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. Vascular Pharmacology, 2020, 135, 106805.	2.1	39
42	Methotrexate inhibits SARSâ€CoVâ€2 virus replication â€œin vitroâ€• Journal of Medical Virology, 2021, 93, 1780-1785.	5.0	38
43	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Clinical Microbiology and Infection, 2016, 22, 288.e1-288.e8.	6.0	33
44	Is Metabolic Syndrome Associated to HIV Infection Per Se? Results from the HERMES Study. Current HIV Research, 2010, 8, 165-171.	0.5	31
45	Novel antiretroviral drugs and renal function monitoring of HIV patients. AIDS Reviews, 2014, 16, 144-51.	1.0	31
46	Cardiovascular Risk Assessment in Antiretroviral-NaÃ¯ve HIV Patients. AIDS Patient Care and STDs, 2009, 23, 809-813.	2.5	29
47	Efficacy and safety of boosted and unboosted atazanavirâ€containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Medicine, 2010, 11, 40-45.	2.2	29
48	Relations between cardiovascular risk estimates and subclinical atherosclerosis in naÃ¯ve HIV patients: results from the HERMES study. International Journal of STD and AIDS, 2010, 21, 267-272.	1.1	29
49	Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study. BMC Infectious Diseases, 2019, 19, 555.	2.9	29
50	Renal complications in HIV disease: between present and future. AIDS Reviews, 2012, 14, 37-53.	1.0	29
51	Metabolic Syndrome: A Real Threat for HIV-Positive Patients?. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 128-131.	2.1	28
52	Raltegravir central nervous system tolerability in clinical practice. Aids, 2012, 26, 2412-2415.	2.2	28
53	The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19. PLoS ONE, 2021, 16, e0246170.	2.5	27
54	Factors associated with hospital admission for COVID-19 in HIV patients. Aids, 2020, 34, 1983-1985.	2.2	26

#	Article	IF	Citations
55	Hypothyroidism in HIVâ€Infected Patients Who Have or Have Not Received HAART. Clinical Infectious Diseases, 2004, 38, 596-597.	5.8	25
56	Haart Tolerability: Post-Exposure Prophylaxis in Healthcare Workers versus Treatment in HIV-Infected Patients. Antiviral Therapy, 2000, 5, 195-197.	1.0	25
57	HIV disease treatment in the era of HAART. Biomedicine and Pharmacotherapy, 1999, 53, 93-105.	5.6	24
58	Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomedicine and Pharmacotherapy, 2004, 58, 505-508.	5.6	24
59	Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. International Journal of Antimicrobial Agents, 2015, 45, 289-294.	2.5	24
60	The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile . Drug Design, Development and Therapy, 2020, Volume 14, 5515-5520.	4.3	24
61	The Cost of HIV Disease in Northern Italy: The Payer's Perspective. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 211-217.	2.1	23
62	Risk factors for lipodystrophy in the CISAI cohort. Biomedicine and Pharmacotherapy, 2003, 57, 422-427.	5.6	22
63	Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa481.	0.9	22
64	Patient-Reported Symptoms and Sequelae 12 Months After COVID-19 in Hospitalized Adults: A Multicenter Long-Term Follow-Up Study. Frontiers in Medicine, 2022, 9, 834354.	2.6	22
65	Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients. Journal of Hypertension, 2017, 35, 409-416.	0.5	21
66	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 1363-1367.	3.0	21
67	Hypersensitivity reactions during antiretroviral regimens with prolease inhibitors. Aids, 1997, 11, 1301-1302.	2.2	20
68	Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric caseâ€“control study. Journal of Bone and Mineral Metabolism, 2011, 29, 383-388.	2.7	20
69	The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: Results from a prospective study. Biomedicine and Pharmacotherapy, 2012, 66, 348-353.	5.6	20
70	Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine, 2022, 47, 101409.	7.1	20
71	Negative Influence of HIV Infection on Day-Night Blood Pressure Variability. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 356-360.	2.1	19
72	Symmetric ambulatory arterial stiffness index and 24-h pulse pressure in HIV infection. Journal of Hypertension, 2013, 31, 560-567.	0.5	19

#	Article	IF	Citations
73	New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy). BMC Infectious Diseases, 2015, 15, 323.	2.9	19
74	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. BMC Public Health, 2018, 18, 870.	2.9	19
75	Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project . Infection and Drug Resistance, 2019, Volume 12, 1385-1391.	2.7	19
76	Evolution of major nonâ€HIVâ€related comorbidities in HIVâ€infected patients in the Italian Cohort of Individuals, NaÃ¯ve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004â€“2014. HIV Medicine, 2019, 20, 99-109.	2.2	19
77	Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir. Aids, 2005, 19, 1433-1434.	2.2	17
78	Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS ONE, 2017, 12, e0179254.	2.5	17
79	Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. Infection and Drug Resistance, 2018, Volume 11, 615-623.	2.7	17
80	Secondary hyperparathyroidism in HIV patients. Aids, 2011, 25, 1430-1433.	2.2	16
81	Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project). Biomedicine and Pharmacotherapy, 2013, 67, 293-298.	5.6	16
82	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 735-741.	3.0	16
83	Being a Doctor Will Never Be the Same After the COVID-19 Pandemic. American Journal of Medicine, 2020, 133, 652.	1.5	16
84	Risk Factors for Hepatotoxicity in Patients Treated With Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 316-318.	2.1	15
85	Mother-To-Child Transmission of KPC Carbapenemase-Producing Klebsiella Pneumoniae at Birth. Pediatric Infectious Disease Journal, 2017, 36, 228-229.	2.0	15
86	Comparison of three therapeutic regimens for genotypeâ€3 hepatitis C virus infection in a large realâ€life multicentre cohort. Liver International, 2020, 40, 769-777.	3.9	15
87	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. AIDS Patient Care and STDs, 2021, 35, 342-353.	2.5	15
88	Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study. BMC Public Health, 2020, 20, 734.	2.9	15
89	Predictors of protease inhibitor-associated adverse events. Biomedicine and Pharmacotherapy, 2001, 55, 321-323.	5.6	14
90	First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006). Infection, 2007, 35, 134-142.	4.7	14

#	Article	IF	Citations
91	Cost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?. ClinicoEconomics and Outcomes Research, 2012, 4, 245.	1.9	14
92	Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 339-345.	2.1	14
93	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. Journal of Antimicrobial Chemotherapy, 2019, 74, 3295-3304.	3.0	14
94	Atrial Fibrillation and Clinical Outcomes in a Cohort of Hospitalized Patients with Sars-Cov-2 Infection and Chronic Kidney Disease. Journal of Clinical Medicine, 2021, 10, 4108.	2.4	14
95	Safety of Statin Therapy in HIV/Hepatitis C Virus-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 258-260.	2.1	13
96	Chronological and biological age in HIV infection. Journal of Infection, 2010, 61, 428-430.	3.3	13
97	Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World. PLoS ONE, 2013, 8, e57777.	2.5	13
98	Firstâ€line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison. HIV Medicine, 2018, 19, 475-484.	2.2	13
99	The effect of frailty on in-hospital and medium-term mortality of patients with COronaVIrus Disease-19: the FRACOVID study. Panminerva Medica, 2022, 64, .	0.8	13
100	The Problem of Renal Function Monitoring in Patients Treated With the Novel Antiretroviral Drugs. HIV Clinical Trials, 2014, 15, 87-91.	2.0	12
101	High parathyroid hormone concentration in tenofovir-treated patients are due to inhibition of calcium-sensing receptor activity. Biomedicine and Pharmacotherapy, 2018, 97, 969-974.	5.6	12
102	The impact of DAAâ€mediated HCV eradication on CD4⁺ and CD8⁺ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort. Journal of Viral Hepatitis, 2021, 28, 779-786.	2.0	12
103	Cholesterol levels in HIVâ€“HCV infected patients treated with lopinavir/r: Results from the SCOLTA project. Biomedicine and Pharmacotherapy, 2008, 62, 16-20.	5.6	11
104	Knowledge transfer: what drug information would specialist doctors need to support their clinical practice? Results of a survey and of three focus groups in Italy. BMC Medical Informatics and Decision Making, 2016, 16, 115.	3.0	11
105	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naÃ¯ve patients with CD4<200 cells/uL (the PRADAR study). PLoS ONE, 2019, 14, e0222650.	2.5	11
106	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. Journal of Antimicrobial Chemotherapy, 2019, 74, 2732-2741.	3.0	11
107	Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade. HIV Medicine, 2022, 23, 70-79.	2.2	11
108	Gender differences in HIV infection: Is there a problem? Analysis from the SCOLTA cohorts. Biomedicine and Pharmacotherapy, 2014, 68, 385-390.	5.6	10

#	Article	IF	Citations
109	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 2663-2669.	3.0	10
110	Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections. Journal of Clinical Medicine, 2021, 10, 1127.	2.4	10
111	Clonal hematopoiesis is not significantly associated with COVID-19 disease severity. Blood, 2022, 140, 1650-1655.	1.4	10
112	Isolated acute dysphagia due to varicella-zoster virus. Journal of Clinical Virology, 2014, 59, 268-269.	3.1	9
113	Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients. Therapeutics and Clinical Risk Management, 2017, Volume 13, 787-797.	2.0	9
114	Employment of recombinant human granulocyte-macrophage colony stimulating factor in oesophageal candidiasis in AIDS patients. Aids, 1995, 9, 1378.	2.2	8
115	Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Therapeutics and Clinical Risk Management, 2012, 8, 377.	2.0	8
116	Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. Biomedicine and Pharmacotherapy, 2015, 69, 233-236.	5.6	8
117	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. Journal of Antimicrobial Chemotherapy, 2018, 73, 3460-3470.	3.0	8
118	Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study. Open Forum Infectious Diseases, 2019, 6, ofz331.	0.9	8
119	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. Journal of Antimicrobial Chemotherapy, 2020, 75, 681-689.	3.0	8
120	Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy. Emerging Infectious Diseases, 2021, 27, 1416-1426.	4.3	8
121	Reversibility of Central Nervous System Adverse Events in Course of Art. Viruses, 2022, 14, 1028.	3.3	8
122	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. PLoS ONE, 2015, 10, e0124252.	2.5	7
123	Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, e76-e79.	1.5	7
124	HIV and SARS-CoV-2 Co-Infection: What are the Risks?. Infection and Drug Resistance, 2021, Volume 14, 3991-4014.	2.7	7
125	Waist circumference and body mass index in HIV infection. HIV Medicine, 2011, 12, 124-125.	2.2	6
126	Decreasing cardiovascular risk in HIV infection between 2005 and 2011. Aids, 2014, 28, 609-612.	2.2	6

#	Article	IF	Citations
127	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 3085-3094.	3.0	6
128	Assessing access to MRI of patients with magnetic resonance-conditional pacemaker and implantable cardioverter defibrillator systems. Journal of Cardiovascular Medicine, 2015, 16, 715.	1.5	6
129	Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort. AIDS Research and Human Retroviruses, 2020, 36, 19-26.	1.1	6
130	Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort . Infection and Drug Resistance, 2020, Volume 13, 2291-2300.	2.7	6
131	The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing Regimens in Treatment-Experienced HIV-1 Infected Patients. Current HIV Research, 2013, 11, 179-186.	0.5	6
132	Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Realâ€Life Cohort Study. Hepatology Communications, 2022, 6, 867-877.	4.3	6
133	Durability of Lopinavir/ritonavir mono-therapy in individuals with viral load â‰50 copies/mL in the observational setting. Antiviral Therapy, 2013, 19, 319-324.	1.0	5
134	Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA). AIDS Research and Therapy, 2019, 16, 21.	1.7	5
135	Response to Antiretroviral Therapy in a Patient with an Uncommon Codon 69 Insertion in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrobial Agents and Chemotherapy, 2000, 44, 1767-1768.	3.2	4
136	Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Journal of the International AIDS Society, 2014, 17, 19769.	3.0	4
137	Streptococcus agalactiae infective endocarditis complicated by multiple mycotic hepatic aneurysms and massive splenic infarction: a case report. BMC Gastroenterology, 2017, 17, 170.	2.0	4
138	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. BMC Public Health, 2019, 19, 1291.	2.9	4
139	Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible From the STOPSHIV Project Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 496-503.	2.1	4
140	Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity. Biomedicine and Pharmacotherapy, 1999, 53, 286-287.	5.6	3
141	Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort. PLoS ONE, 2014, 9, e89861.	2.5	3
142	HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy. PLoS ONE, 2016, 11, e0168399.	2.5	3
143	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCVâ€infected patients treated in a realâ€life setting. Journal of Viral Hepatitis, 2021, 28, 558-568.	2.0	3
144	HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation. HIV Medicine, 2021, 22, 860-866.	2.2	3

#	Article	IF	Citations
145	Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. AIDS Reviews, 2005, 7, 161-7.	1.0	3
146	Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers. Sexually Transmitted Infections, 2023, 99, 41-46.	1.9	3
147	Assessing the mortality risk in older patients hospitalized with a diagnosis of sepsis: the role of frailty and acute organ dysfunction. Aging Clinical and Experimental Research, 2022, 34, 2335-2343.	2.9	3
148	Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy. Aids, 2015, 29, 2061-2062.	2.2	2
149	Effectiveness of first-generation HCV protease inhibitors. European Journal of Gastroenterology and Hepatology, 2016, 28, 37-41.	1.6	2
150	Genotype 3 infection in DAA era: Reports of a real life Northern Italy Network for viral hepatitis after 2 years by the start. Digestive and Liver Disease, 2017, 49, e68.	0.9	2
151	Mother-to-child transmission of KPC-producing Klebsiella pneumoniae : potential relevance of a low microbial urinary load for screening purposes. Journal of Hospital Infection, 2018, 98, 314-316.	2.9	2
152	Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study. New Microbiologica, 2014, 37, 439-48.	0.1	2
153	Neurovascular and infectious disease phenotype of acute stroke patients with and without COVID-19. Neurological Sciences, 2022, 43, 4619-4625.	1.9	2
154	Bilateral carotid stenosis in a young female HIV patient treated with highly active antiretroviral therapy. Aids, 2002, 16, 2225-2227.	2.2	1
155	Low frequency of skin reactions in a cohort of patients on raltegravir. Journal of Antimicrobial Chemotherapy, 2012, 67, 1800-1802.	3.0	1
156	THU-180-Treatment of genotype 3 HCV infection in the large real-life â€œNavigatore Lombardiaâ€• multicentre cohort: Results from three different regimens. Journal of Hepatology, 2019, 70, e241.	3.7	1
157	Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: Is There an Optimal Interleukin 6 Cutoff for Successful Tocilizumab Treatment?. Clinical Infectious Diseases, 2020, 73, e270-e271.	5.8	1
158	miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis. International Journal of Molecular Sciences, 2022, 23, 3486.	4.1	1
159	Prevalence and factors associated with idiopathic hypercalciuria in HIV patients on combination antiretroviral therapy. International Journal of STD and AIDS, 2010, 21, 829-831.	1.1	0
160	Zika virus infections in travellers and contacts in Lombardy, Northern Italy 2016. Journal of Clinical Virology, 2016, 82, S21.	3.1	0
161	Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks. Digestive and Liver Disease, 2019, 51, e15.	0.9	0
162	The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data. Infection and Drug Resistance, 2021, Volume 14, 1389-1392.	2.7	0

#	Article	IF	Citations
163	COVID-19 Mortality and Stress to the Hospital System From High Patient Load. JAMA Internal Medicine, 2021, 181, 1134.	5.1	0
164	Comments on â€œRealâ€world reâ€treatment outcomes of directâ€acting antiviral therapy failure in patients with chronic hepatitis Câ€. Journal of Medical Virology, 2022, 94, 436-438.	5.0	0
165	First-line HIV treatment: evaluation of backbone choice and its budget impact. Farmeconomia E Percorsi Terapeutici, 2013, 14, 75-87.	0.1	0
166	Ebola: what we have learned. Reviews in Health Care, 2014, 5, 149-152.	0.1	0
167	Simulating the development and progression of Chronic Kidney Disease and osteoporosis in people living with HIV. Farmeconomia E Percorsi Terapeutici, 2016, 17, 3-23.	0.1	0
168	SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients. New Microbiologica, 2019, 42, 150-155.	0.1	0
169	Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection.. Acta Biomedica, 2022, 92, e2021464.	0.3	0